2 citations
,
December 2021 in “Journal of Veterinary Medical Science” Lokivetmab reduced itching in a dog with skin lymphoma.
March 2021 in “International Journal of Clinical Dermatology & Research” Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
2 citations
,
December 2024 in “International Journal of Rheumatic Diseases” Ocrelizumab may cause total body hair loss in some patients.
1 citations
,
January 2025 in “International Journal of Dermatology” Dupilumab can both improve and worsen alopecia areata, with higher IgE levels linked to better outcomes.
29 citations
,
July 2019 in “Dermatologic Therapy” Dupilumab can both heal and cause hair loss.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
November 2025 in “Journal of Pharmaceutical Research International” Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
January 2025 in “International Journal of Medicine in Developing Countries” Ocrelizumab may cause delayed hair loss in some patients.
19 citations
,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
March 2026 in “Indian journal of veterinary and animal sciences research.” A Labrador Retriever with pemphigus fully recovered after six weeks of azathioprine treatment.
2 citations
,
January 2020 in “Skin Appendage Disorders” Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.
68 citations
,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
July 2024 in “Russian Journal of Child Neurology” Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.